Hospital
Wesley Medical Center LLC
Wesley Medical Center LLC was paid $30.22M by Medicaid between Jan 2018 and Nov 2024, across 209 billing codes. Its largest line is 99283, emergency room visit (moderate) — 47% of everything it billed.
33Billing provider infoWESLEY MEDICAL CENTER LLC
WICHITA, KS 67214
WICHITA, KS 67214
33aNPI1447299649assigned 06/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$30.22M
24GClaims747,814
24DCodes billed209
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kansas
Rank by total paid#2 of 48
Median peer was paid$461K
This provider vs. median66×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 129,977 | $4.93M | |
| 2019 | 120,911 | $5.08M | |
| 2020 | 80,804 | $3.52M | |
| 2021 | 97,122 | $4.17M | |
| 2022 | 120,167 | $4.72M | |
| 2023 | 117,278 | $4.23M | |
| 2024incomplete | 81,555 | $3.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 47% | 172,964 | 164,279 | $14.34M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 80,603 | 74,558 | $7.73M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.1% | 37,693 | 36,441 | $2.43M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.2% | 13,945 | 5,264 | $1.26M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 11,703 | 11,304 | $595K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 44,450 | 41,054 | $545K |
| 85027 | 1.2% | 63,598 | 57,043 | $348K | |
| 80053 | Comprehensive metabolic panel | <1% | 36,714 | 32,972 | $282K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,141 | 12,811 | $256K |
| 71045 | Radiologic examination, chest; single view | <1% | 20,377 | 18,969 | $246K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,233 | 14,999 | $203K |
| 81025 | <1% | 24,109 | 23,171 | $131K |
197 more codes
| 11045 | <1% | 8,831 | $127K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,703 | $119K |
| 31720 | <1% | 2,651 | $104K | |
| 81001 | <1% | 41,036 | $95K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 454 | $85K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 580 | $71K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 88 | $71K |
| 99285 | Emergency room visit (most serious) | <1% | 488 | $64K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,453 | $63K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,343 | $58K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 651 | $50K |
| 76770 | <1% | 683 | $48K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,797 | $45K |
| 83690 | <1% | 8,733 | $42K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,114 | $41K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 697 | $40K |
| 80047 | <1% | 2,629 | $36K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 713 | $33K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,183 | $31K |
| 84484 | <1% | 4,119 | $31K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 356 | $29K |
| G0378 | Hospital observation service, per hour | <1% | 289 | $27K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,717 | $26K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 733 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 716 | $23K |
| 97602 | <1% | 363 | $18K | |
| 87081 | <1% | 3,086 | $18K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 45 | $16K |
| 12001 | <1% | 85 | $14K | |
| 76801 | <1% | 222 | $14K | |
| 74018 | <1% | 981 | $14K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,908 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,994 | $12K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 148 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 228 | $12K |
| 97605 | <1% | 1,485 | $11K | |
| 10060 | <1% | 66 | $10K | |
| 11043 | <1% | 160 | $10K | |
| 94060 | <1% | 239 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,007 | $10K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 247 | $9K |
| 96409 | <1% | 193 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 220 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,112 | $8K |
| 87186 | <1% | 932 | $8K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 658 | $8K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 211 | $8K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 152 | $7K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 77 | $7K |
| 82248 | <1% | 1,778 | $6K | |
| 97597 | <1% | 55 | $6K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 360 | $6K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 38 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 104 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 122 | $5K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 93 | $5K |
| 29125 | <1% | 24 | $5K | |
| 84112 | <1% | 72 | $5K | |
| 96376 | <1% | 359 | $5K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 183 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 258 | $4K |
| 92588 | <1% | 113 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 78 | $4K |
| 81003 | <1% | 2,947 | $4K | |
| 12011 | <1% | 84 | $4K | |
| 93971 | <1% | 50 | $4K | |
| 87205 | <1% | 1,297 | $4K | |
| 87070 | <1% | 982 | $4K | |
| 36430 | <1% | 12 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 158 | $4K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 67 | $4K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 89 | $3K |
| 87210 | <1% | 843 | $3K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 46 | $3K |
| 83735 | <1% | 273 | $3K | |
| 97116 | <1% | 107 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $2K |
| 70486 | <1% | 28 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 45 | $2K |
| 73610 | <1% | 154 | $2K | |
| 87147 | <1% | 478 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 53 | $2K |
| 73630 | <1% | 148 | $2K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 239 | $2K |
| 87077 | <1% | 293 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 18,139 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 89 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 86 | $2K |
| 93976 | <1% | 48 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 853 | $2K |
| 73130 | <1% | 121 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,889 | $2K |
| 84703 | <1% | 243 | $2K | |
| 84702 | <1% | 176 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,721 | $1K |
| 73110 | <1% | 109 | $1K | |
| 73502 | <1% | 53 | $1K | |
| 87807 | <1% | 63 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,238 | $1K |
| 83880 | <1% | 98 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 822 | $1K |
| 97161 | <1% | 24 | $1K | |
| 86920 | <1% | 13 | $1K | |
| 80076 | <1% | 169 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 683 | $1K |
| 73562 | <1% | 102 | $1K | |
| 92555 | <1% | 68 | $1K | |
| 73030 | <1% | 80 | $1K | |
| 80320 | <1% | 74 | $1K | |
| 83605 | <1% | 110 | $1K | |
| 82728 | <1% | 49 | $974.25 | |
| 92568 | <1% | 101 | $962.81 | |
| 72100 | <1% | 61 | $944.77 | |
| 87040 | <1% | 96 | $934.68 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 14 | $930.90 |
| 73080 | <1% | 54 | $904.25 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 790 | $835.46 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 621 | $834.30 |
| 86850 | <1% | 105 | $786.64 | |
| 85379 | <1% | 97 | $784.59 | |
| 86901 | <1% | 154 | $784.00 | |
| 90715 | <1% | 70 | $753.80 | |
| 85610 | <1% | 194 | $743.42 | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 12 | $729.24 |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 45 | $681.75 |
| 95819 | <1% | 16 | $680.11 | |
| 80061 | Lipid panel | <1% | 61 | $659.89 |
| 87088 | <1% | 69 | $656.83 | |
| 73590 | <1% | 45 | $647.50 | |
| 85014 | <1% | 641 | $615.48 | |
| 76536 | <1% | 27 | $609.11 | |
| 80329 | <1% | 15 | $589.83 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 12 | $587.54 |
| 73140 | <1% | 52 | $576.89 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 111 | $519.59 |
| 95816 | <1% | 12 | $495.22 | |
| 86140 | <1% | 87 | $484.40 | |
| 83615 | <1% | 64 | $462.76 | |
| 97162 | <1% | 12 | $446.58 | |
| 82570 | <1% | 64 | $425.46 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 565 | $393.12 |
| 85046 | <1% | 57 | $380.47 | |
| 86592 | <1% | 86 | $376.76 | |
| 84439 | <1% | 28 | $368.39 | |
| A9270 | Non-covered item or service | <1% | 3,165 | $366.86 |
| 86900 | <1% | 94 | $363.87 | |
| 84550 | <1% | 56 | $359.55 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $356.22 |
| 80069 | <1% | 31 | $319.82 | |
| 77072 | <1% | 27 | $314.44 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 278 | $303.85 |
| 84156 | <1% | 63 | $302.84 | |
| 88307 | <1% | 22 | $298.96 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 146 | $290.30 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 285 | $286.05 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 320 | $235.86 |
| 73564 | <1% | 13 | $220.29 | |
| 82803 | <1% | 13 | $219.91 | |
| 73090 | <1% | 13 | $188.10 | |
| 85730 | <1% | 36 | $169.53 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 40 | $158.29 |
| 87340 | <1% | 14 | $156.57 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15 | $154.86 |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,625 | $151.69 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 19 | $147.77 |
| 88304 | <1% | 17 | $140.40 | |
| 85007 | <1% | 54 | $130.05 | |
| 85018 | <1% | 113 | $128.41 | |
| 82565 | <1% | 28 | $109.38 | |
| 84134 | <1% | 27 | $109.24 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 138 | $105.11 |
| 82550 | <1% | 14 | $99.24 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 380 | $95.14 |
| 85651 | <1% | 24 | $94.38 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 104 | $90.82 |
| 84132 | <1% | 30 | $80.20 | |
| 90686 | <1% | 15 | $58.83 | |
| 84100 | <1% | 15 | $56.29 | |
| 87806 | <1% | 87 | $54.62 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 51 | $49.77 |
| 96127 | <1% | 22 | $47.70 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 49 | $38.29 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,380 | $37.60 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 72 | $36.93 |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 14 | $30.38 |
| J3490 | Unclassified drugs | <1% | 70 | $19.46 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 55 | $15.68 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 385 | $4.90 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 19 | $3.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 111 | $2.40 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 21 | $0.00 |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | 0% | 30 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 156 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 182 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 36 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 29 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 92 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCASTLEBERRY, NICOLE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Wesley Medical Center LLC | Wichita, KS | $284K |
| Wesley Medical Center LLC | Wichita, KS | $56K |
| Wesley Medical Center LLC | Wichita, KS | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.